A 12-week open-label, randomized, controlled trial and 24-week extension to assess the efficacy and safety of fluticasone propionate/formoterol in children with asthma

Therapeutic Advances in Respiratory Disease

Volumn 10, Issue 4, 2016, Pages 324-337

  Emeryk, Andrzej ^a   Klink, Rabih ^b   McIver, Tammy ^c   Dalvi, Prashant ^c  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b Cabinet de Pédiatrie et de Pneumo Allergologie Pédiatriques   (France)

^c Mundipharma Research   (United Kingdom)

Author keywords

asthma; children; combination therapy; fluticasone propionate; formoterol fumarate; pMDI

Indexed keywords

FLUTICASONE PROPIONATE PLUS FORMOTEROL FUMARATE; FLUTICASONE PROPIONATE PLUS SALMETEROL XINAFOATE; HYDROCORTISONE; ANDROSTANE DERIVATIVE; ANTIASTHMATIC AGENT; BRONCHODILATING AGENT; ETHANOLAMINE DERIVATIVE; FLUTICASONE PROPIONATE PLUS SALMETEROL;

AGE DISTRIBUTION; ARTICLE; ASTHMA; BRONCHITIS; CHILD; CONTROLLED STUDY; COUGHING; DISEASE EXACERBATION; DIZZINESS; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INFECTION COMPLICATION; INFESTATION; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; OUTCOME ASSESSMENT; PEAK EXPIRATORY FLOW; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RHINOPHARYNGITIS; SCHOOL CHILD; THORAX DISEASE; THRUSH; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG COMBINATION; LUNG FUNCTION TEST; TREATMENT OUTCOME;

ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHODILATOR AGENTS; CHILD; CHILD, PRESCHOOL; DRUG COMBINATIONS; ETHANOLAMINES; FEMALE; FLUTICASONE-SALMETEROL DRUG COMBINATION; FORCED EXPIRATORY VOLUME; HUMANS; MALE; PEAK EXPIRATORY FLOW RATE; RESPIRATORY FUNCTION TESTS; TREATMENT OUTCOME;

EID: 84979265869     PISSN: 17534658     EISSN: 17534666     Source Type: Journal    
DOI: 10.1177/1753465816646320     Document Type: Article

References (47)

1. Aalbers R., Brusselle G., McIver T., Grothe B., Bodzenta-Lukaszyk A., (2012) Onset of bronchodilation with fluticasone/formoterol combination versus fluticasone/salmeterol in an open-label, randomized study. Adv Ther 29: 958-969.
2. Allen D., (2006) Effects of inhaled steroids on growth, bone metabolism, and adrenal function. Adv Pediatr 53: 101-110.
3. Bodzenta-Lukaszyk A., Buhl R., Balint B., Lomax M., Spooner K., (2012) Fluticasone/formoterol combination therapy versus budesonide/formoterol for the treatment of asthma: a randomised, controlled, non-inferiority trial of efficacy and safety. J Asthma 49: 1060-1070.
4. Bodzenta-Lukaszyk A., Dymek A., McAulay K., Mansikka H., (2011a) Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study. BMC Pulm Med 11: 28.
5. Bodzenta-Lukaszyk A., Pulka G., Dymek A., Bumbacea D., McIver T., Schwab B., et al. (2011b) Efficacy and safety of fluticasone and formoterol in a single pressurized metered dose inhaler. Respir Med 105: 674-682.
6. National Center for Health Statistics-CDC (2000) United States Growth Charts. Available at: http://www.cdc.gov (. accessed 25 March 2015).
7. Corren J., Mansfield L., Pertseva T., Blahzko V., Kaiser K., (2012) Efficacy and safety of fluticasone/formoterol combination therapy in patients with moderate-to-severe asthma. Respir Med 107: 180-195.
8. 2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database Syst Rev 5: CD005535.
9. Ernst P., Gonzalez A., Brassard P., Suissa S., (2007) Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 176: 162-166.
10. Global Initiative for Asthma (GINA). (2015) Global strategy for asthma management and prevention. Available from: www.ginasthma.org. Accessed 25 March 2015.
11. Halpin D., Gray J., Edwards S., Morais J., Singh D., (2011) Budesonide/formoterol versus salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials. Int J Clin Pract 65: 764-774.
12. Hamill J., Spyridon M., (2014) Real world evidence on asthma review and change from fluticasone propionate/salmeterol to fluticasone propionate/formoterol. Prim Care Respir Med 24: 14110 (abstract 11).
13. ICH (2010) International conference on harmonization of technical requirements for registration of pharmaceuticals for human use: choice of control group and related issues in clinical trials. Efficacy Guideline ICH E10. Available at: http://www.ich.org/products/guidelines/efficacy/article/efficacy-guidelines.html (. accessed 11 April 2016).
14. Janson C., Larsson K., Lisspers K., Ställberg B., Stratelis G., Goike H., et al. (2013) Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting beta2 agonist: observational matched cohort study (PATHOS). BMJ 346: f3306.
15. Lasserson T., Ferrara G., Casali L., (2008) Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children. Cochrane Database Syst Rev 3: CD004106.
16. Lemanske Jr. R., Mauger D., Sorkness C., Jackson D., Boehmer S., Martines F., et al. (2010) Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med 362: 975-985.
17. Lim D., Small I., Wolfe S., Hamill J., Gruffydd-Jones K., Daly C., et al. (2014) Real world effectiveness of changing fixed-dose combination therapy from Seretide® MDI to Flutiform® in UK asthma patients. 7th World Conference of the International Primary Care Respiratory Group (IPCRG). Athens, Greece.
18. Mansur A., Kaiser K., (2013) Long-term safety and efficacy of fluticasone/formoterol combination therapy in asthma. J Aerosol Med Pulm Drug Deliv 26: 190-199.
19. Morice A., Peterson S., Beckman O., Kukova Z., (2008) Efficacy and safety of a new pressurised metered-dose inhaler formulation of budesonide/formoterol in children with asthma: a superiority and therapeutic equivalence study. Pulm Pharmacol Ther 21: 152-159.
20. Murphy K., Bender B., (2009) Treatment of moderate to severe asthma: patient perspectives on combination inhaler therapy and implications for adherence. J Asthma Allergy 2: 63-72.
21. Murphy D., O'Byrne P., (2010) Recent advances in the pathophysiology of asthma. Chest 137: 1417-1426.
22. Nannini L., Lasserson T., Poole P., (2012) Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 9: CD006829.
23. Nathan R., D'Urzo A., Blazhko V., Kaiser K., (2012) Safety and efficacy of fluticasone/formoterol combination therapy in adolescent and adult patients with mild-to-moderate asthma: a randomised controlled trial. BMC Pulm Med 12: 67.
24. National Heart, Lung, and Blood Institute (2007) Expert panel report 3: guidelines for the diagnosis and management of asthma. National Asthma Education and Prevention Program, third expert panel on the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute. Available at: http://www.ncbi.nlm.nih.gov/books/NBK7232/ (. accessed 25 March 2015).
25. Ni Chroinin M., Greenstone I., Lasserson T., Ducharme F., (2009) Addition of long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naïve adults and children (review). Cochrane Database Syst Rev 4: CD005307.
26. O'Byrne P., Bisgaard H., Godard P., Pistolesi M., Palmqvist M., Zhu Y., et al. (2005) Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 171: 129-136.
27. O'Byrne P., Pedersen S., Carlsson L., Radner F., Thorén A., Peterson S., et al. (2011) Risks of pneumonia in patients with asthma taking inhaled corticosteroids. Am J Respir Crit Care Med 183: 589-595.
28. Palmqvist M., Persson G., Lazer L., Rosenborg J., Larsson P., Lotvall J., (1997) Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J 10: 2484-2489.
29. Papi A., Mansur A., Dissanayake S., Pertseva T., McIver T., Kaiser K., (2013) Long-term fluticasone propionate/formoterol fumarate combination therapy is associated with a low incidence of severe asthma exacerbations. Respirology 18: 111-114.
30. Papi A., Price D., Sastre J., Kaiser K., Lomax M., McIver T., et al. (2015) Efficacy of fluticasone propionate/formoterol fumarate in the treatment of asthma: A pooled analysis. Respir Med 109: 208-217.
31. Pearlman D., LaForce C., Kaiser K., (2013) Fluticasone/Formoterol combination therapy compared with monotherapy in adolescent and adult patients with mild to moderate asthma. Clin Ther 35: 950-966.
32. Pedersen S., (2001) Do inhaled corticosteroids inhibit growth in children? Am J Respir Crit Care Med 164: 521-535.
33. Pertseva T., Dissanayake S., Kaiser K., (2013) Superiority of fluticasone propionate/formoterol fumarate versus fluticasone propionate alone in patients with moderate-to-severe asthma: a randomised controlled trial. Curr Med Res Opin 29: 1357-1369.
34. Ploszczuk A., Bosheva M., Spooner K., McIver T., Dissanayake S., (2014) Efficacy and safety of fluticasone propionate/formoterol in paediatric patients with asthma. Eur Respir J 44: Abstract 1167.
35. Pohunek P., Kuna P., Jorup C., De Boeck K., (2006) Budesonide/formoterol improves lung function compared with budesonide alone in children with asthma. Pediatr Allergy Immunol 17: 458-465.
36. Politiek M., Boorsma M., Aalbers R., (1999) Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction. Eur Respir J 13: 988-992.
37. Reddel H., Taylor D., Bateman E., Boulet L., Boushey H., Busse W., et al. (2009) An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 180: 59-99.
38. Robinson J., Angelini B., Krahnke J., Skoner D., (2002) Inhaled steroids and the risk of adrenal suppression in children. Expert Opin Drug Saf 1: 237-244.
39. Roe R., Junor R., (2014) Real-world insights into treatment persistence with fluticasone propionate/ formoterol (FP/FORM) combination inhaler. npj Prim Care Respir Med 24: 14110 (abstract 27).
40. Rosenhall L., Elvstrand A., Tilling B., Vinge I, Jemsby P., Ståhl E., et al. (2003) One-year safety and efficacy of budesonide/formoterol in a single inhaler (Symbicort Turbuhaler) for the treatment of asthma. Respir Med 97: 702-708.
41. Sorkness C., Lemanske R. Jr., Mauger D., Boehmer S., Chinchilli V., Martines F., et al. (2007) Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: the Pediatric Asthma Controller Trial. J Allergy Clin Immunol 119: 64-72.
42. Todd G., Acerini C., Ross-Russell R., Zahra S., Warner J., McCance D., (2002) Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Arch Dis Child 87: 457-461.
43. Vaessen-Verberne A., van den Berg N., van Nierop J., Brackel H., Gerrits G., Hop W., et al. (2010) Combination therapy salmeterol/fluticasone versus doubling dose of fluticasone in children with asthma. Am J Respir Crit Care Med 182: 1221-1227.
44. Wedzicha J., Calverley P., Seemungal T., Hagan G., Ansari Z., Stockley R., (2008) The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 177: 19-26.
45. Wei L., Lin D., Weissfeld L., (1989) Regression analysis of multivariate incomplete failure time data by modelling marginal distributions. J Am Stat Assoc 84: 1065-1073.
46. Wolthers O., Moore A., Mersmann S., Dissanayake S., (2015) Knemometry assessment of short-term lower leg growth in children with asthma treated with fluticasone propionate/formoterol combination therapy. Eur Respir J 46: PA1292.
47. Zapletal A., Paul T., Samanek M., (1977) [Significance of contemporary methods of lung function testing for the detection of airway obstruction in children and adolescents (author's transl)]. Z Erkr Atmungsorgane 149: 343-371.